Tin tức & Cập nhật

Efruxifermin shows therapeutic potential alongside GLP-1RA medications

09 Mar 2024

Treatment with the Fc–FGF21 analogue efruxifermin is well tolerated and appears to further improve liver health in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis who are already on a GLP-1RA, according to a phase IIb trial.

Efruxifermin shows therapeutic potential alongside GLP-1RA medications

09 Mar 2024

Computer-aided detection of colonic neoplasia yields modest improvements

08 Mar 2024

The use of real-time, computer-aided detection of colonic neoplasia leads to modest increases in adenoma detection rate and adenomas detected per colonoscopy in average-detector community endoscopists, as shown in the results of a pragmatic randomized controlled trial.

Computer-aided detection of colonic neoplasia yields modest improvements

08 Mar 2024

DASH, plant-based diets help prevent gastrointestinal cancers

06 Mar 2024

People who follow a healthy eating pattern, such as the dietary approach to stop hypertension (DASH) or the healthful plant-based diet index (hPDI), have a lower risk of gastrointestinal cancers (GIC), suggests a study. These dietary patterns also appear to partly compensate for genetic predispositions to cancer.

DASH, plant-based diets help prevent gastrointestinal cancers

06 Mar 2024

Inflammatory bowel disease tied to pancreatic cancer risk

05 Mar 2024

Patients with inflammatory bowel disease (IBD) appear to have a moderately elevated risk of pancreatic cancer, according to a meta-analysis.

Inflammatory bowel disease tied to pancreatic cancer risk

05 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024 bởi

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 bởi

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.